Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Launched by JONSSON COMPREHENSIVE CANCER CENTER · Apr 18, 2018
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patient has undergone or has elected to undergo hemi-gland cryoablation at UCLA
- • Low or intermediate risk prostate cancer (Gleason ≤ 7) or select high-risk patients (Gleason 8 prostate cancer).
- • Prostate volume of ≤ 70 cc
- • Ability to complete informed consent form
- Exclusion criteria:
- • Medical contraindication to follow-up multi-parametric magnetic resonance imaging (mpMRI) or prostate biopsy
- • Patients unable to tolerate general or regional anesthesia.
About Jonsson Comprehensive Cancer Center
The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Leonard S Marks, MD
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials